JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

Search

Ovid therapeutics Inc

Suletud

SektorTervishoid

1.37 -5.52

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.3599999999999999

Max

1.46

Põhinäitajad

By Trading Economics

Sissetulek

5.6M

-4.7M

Müük

6.1M

6.3M

Kasumimarginaal

-74.681

Töötajad

23

EBITDA

7.3M

-5.1M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+222.07% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

10. nov 2025

Turustatistika

By TradingEconomics

Turukapital

74M

114M

Eelmine avamishind

6.89

Eelmine sulgemishind

1.37

Uudiste sentiment

By Acuity

67%

33%

331 / 373 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Ovid therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. okt 2025, 23:32 UTC

Kuumad aktsiad

Stocks to Watch: Amazon, Reddit, SPS Commerce

30. okt 2025, 23:02 UTC

Tulu

AIA Group 3Q Value of New Business Grew

30. okt 2025, 23:45 UTC

Market Talk

Gold Edges Higher Amid Prospects of Continued Central-Bank Demand -- Market Talk

30. okt 2025, 23:00 UTC

Tulu

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 3rd Update

30. okt 2025, 22:59 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

30. okt 2025, 22:59 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Mineral Resources Bear Reckons Lithium Assets May Be Dressed Up For Sale -- Market Talk

30. okt 2025, 22:56 UTC

Market Talk

Australia Shares Shaping to Pare Recent Losses -- Market Talk

30. okt 2025, 22:35 UTC

Tulu

AIA Group 3Q Value of New Business Margin Was 58.2%, Up 5.7 Ppt on Year >1299.HK

30. okt 2025, 22:35 UTC

Tulu

AIA Group 3Q Value of New Business $1.48B Vs. $1.16B>1299.HK

30. okt 2025, 22:31 UTC

Tulu

Apple Expects Big December Quarter on iPhone Upgrades -- 2nd Update

30. okt 2025, 22:29 UTC

Tulu

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 2nd Update

30. okt 2025, 22:27 UTC

Tulu

Minas Buenaventura 3Q EPS 66c >BVN

30. okt 2025, 22:27 UTC

Tulu

Minas Buenaventura 3Q Rev $431M >BVN

30. okt 2025, 22:27 UTC

Tulu

Minas Buenaventura 3Q Net $179M >BVN

30. okt 2025, 22:16 UTC

Market Talk
Tulu

Amazon's Grocery Delivery Business Gains Ground -- Market Talk

30. okt 2025, 22:14 UTC

Tulu

Review & Preview: A Tech Earnings Storm -- Barrons.com

30. okt 2025, 22:00 UTC

Tulu
Omandamised, ülevõtmised, äriostud

The Day Pharma's Weight-Loss Gold Rush Intensified -- WSJ

30. okt 2025, 21:39 UTC

Tulu

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30. okt 2025, 21:26 UTC

Tulu

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30. okt 2025, 21:14 UTC

Market Talk
Tulu

Apple Sees Record Quarterly Services Revenue -- Market Talk

30. okt 2025, 21:09 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

30. okt 2025, 21:09 UTC

Market Talk
Tulu

Amazon Says One-Off Costs Ate Into Operating Income -- Market Talk

30. okt 2025, 21:04 UTC

Tulu

Apple Expects Big December Quarter on iPhone Upgrades -- Update

30. okt 2025, 21:03 UTC

Tulu

Eldorado Gold 3Q Gold Sales Were 116,529 Ounces at Avg Realized Gold Price Per Ounce Sold of $3,527 >ELD.T

30. okt 2025, 21:03 UTC

Tulu

Eldorado Gold 3Q Gold Production Was 115,190 Ounces >ELD.T

30. okt 2025, 21:00 UTC

Tulu

Eldorado Gold Skouries on Track for 1Q of 2026

30. okt 2025, 21:00 UTC

Tulu

Eldorado Gold 3Q Adj EPS 41c >EGO

30. okt 2025, 21:00 UTC

Tulu

Eldorado Gold 3Q Rev $434.7M >EGO

30. okt 2025, 21:00 UTC

Tulu

Eldorado Gold 3Q Net $56M >EGO

30. okt 2025, 21:00 UTC

Tulu

Eldorado Gold 3Q EPS 27c >EGO

Võrdlus sarnastega

Hinnamuutus

Ovid therapeutics Inc Prognoos

Hinnasiht

By TipRanks

222.07% tõus

12 kuu keskmine prognoos

Keskmine 4.67 USD  222.07%

Kõrge 7 USD

Madal 1.5 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Ovid therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

8

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.275 / 0.33Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

331 / 373 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat